For Patients


Foundation for Thymic Cancer Research



You are not alone!


contact us

Upcoming events

RECORDINGS – Webinars for Patients 2021: EXPERTS EXPLAIN

In 2021 ITMIG invites thymic epithelial tumor patients for a new series of webinars: EXPERTS EXPLAIN. Our experts are explaining the meaning of many definitions and are answering patients’ questions related with diagnosis and treatment of thymic epithelial tumors. Each webinar contain short presentation(s) and live Q&A (Questions and Answers) part.

Main organizers:

Malgorzata Szolkowska, pathologist, the National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Pam Bruce, Executive Director of ITMIG, New York, USA

Edith Marom, diagnostic radiologist, The Chaim Sheba Medical Center, Ramat Gan, Israel


This is a recording of the first webinar.

The video contains two presentations dedicated to radiological and histopathological definitions:

1. “Imaging of thymic tumors”, Dr. Chad Strange, Assistant Professor of Thoracic Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA;

2.“How should I understand my diagnosis?”, Dr. Jan von der Thüsen, Consultant Histopathologist, Erasmus MC, University Medical Center Rotterdam, The Netherlands.

Moderator of the webinar: Dr. Malgorzata Szolkowska from the National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland



The second webinar was dedicated to surgical treatment of thymic tumors.

Our expert,

Dr. Paul Van Schil, from the Thoracic and Vascular Surgery, the Antwerp University Hospital, Edegem (Antwerp), Belgium

was talking about: “Surgical treatment of mediastinal tumours: from maximally invasive to minimally invasive techniques”.

The webinar was moderated by Dr. Usman Ahmad from the Heart, Vascular and Thoracic Institute, the Cleveland Clinic, Cleveland, OH, USA.



In this webinar radiation oncology matters and definitions will be explained.

Dr. Annemarie Fernandes Shepherd, from the Department of Radiation Oncology, the Memorial Sloan Kettering Cancer Center, New York, USA

was talking about “Radiotherapy of thymic epithelial tumors”.

The webinar was moderated by Prof. Conrad Falkson from the Queen’s University and Kingston Health Sciences Center, Kingston, Ontario, Canada.



This time medical oncologist,

Dr. Arun Rajan, from the National Cancer Institute, the National Institutes of Health (NCI/NIH), Bethesda, USA

was explaining oncological issues in a presentation: Oncological Treatment for Advanced Thymic Tumors – Definitions and Strategies.

Moderator of the webinar: Prof. Frank Detterbeck from the Yale University School of Medicine, New Haven, CT, USA.




It is our pleasure to invite you to watch the recording of our last webinar of series EXPERTS EXPLAIN.

Our speakers:
Nicolas Girard, the Institut du Thorax Curie Montsouris, Institut Curie, Paris, France
Arun Rajan, the National Cancer Institute, the National Institutes of Health (NCI/NIH), Bethesda, USA
Heather Wakelee, the Stanford University, Stanford, CA, USA
and Anne Tsao, the University of Texas M.D. Anderson Cancer Center, Houston, USA

are presenting: Clinical Trials for Thymic Epithelial Tumors.

Moderator: Dr. Malgorzata Szolkowska from the National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland

Clinical Trials presented in this webinar

NCT03134118: Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)

NCT02724696: French National Observatory of Patients With Thymic Epithelial Tumor (RYTHMIC) 

NCT04731610: Phase III, Opened, Randomized Study of Post-Operative Radiotherapy (PORT) versus Surveillance in Stage IIB/III of Masaoka Koga Thymoma after Complete Surgical Resection (RADIO-RYTHMIC) 


Institute Curie, Paris, France, 75005

Principal Investigator: Nicolas Girard

NCT04417660: Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma

NCT03076554: Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Contact: Shannon G. Swift, R.N., phone (+1) (240) 858-3157; email: 

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Principal Investigator: Arun Rajan

NCT03583086: Phase I/II Trial of Nivolumab plus Vorolanib in patients with Thymic Carcinoma (and other thoracic cancers)

Contact: phone (+1) 800-811-8480, email:

Stanford Cancer Institute- California

Palo Alto, California, United States, 94304

Principal Investigator: Heather Wakelee

Winship Cancer Institute, Emory University- Georgia

Atlanta, Georgia, United States, 30322

Principal Investigator: Badi El Osta

University of Chicago Medical Center – Illinois

Chicago, Illinois, United States, 60637

Principal Investigator: Christine Bestvina

Baptist Clinical Research Institute – Tennessee

Memphis, Tennessee, United States, 38120

Contact: Baptist Cancer Center Clinical Research Office

Principal Investigator: Philip Lammers

Vanderbilt-Ingram Cancer Center – Tennessee * Coordinating Center

Nashville, Tennessee, United States, 37232

NCT03694002: Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

NCT03295227: Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma

Contact: Anne S. Tsao, phone (+1) 713-792-6363, email: 

University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Principal Investigator: Anne S. Tsao


Thank you for attending our webinars!

Rare cancers of the thymus. What they are and how you can help.

Geralyn Johnson, a patient fighting with a thymoma – the malignant neoplasm of the thymus, talks about this rare disease and the activity of the International Thymic Malignancy Working Group (ITMIG).

There are active groups on Facebook for Thymoma/Thymic Carcinoma patients and others interested in these diseases

Here are some statistics about the Thymoma Support Group. This group has 2300 members from 94 countries! The highest populations are from the US, UK, AUS, Philippines & Canada, respectively. The group is split 74% woman & 26% men. Age ranges are 35-44 being the most followed by 45-54, 55-64, 25-34, 65+ and then 18-24.


There is also a Thymic Carcinoma group and an ITMIG Advocates group.

Webinar for Patients, 2020/09/22

A summary of a Webinar for Patients is now available.

You can find here:

  • Audio recording of the webinar
  • Presentation of Dr. Arun Rajan
  • Responses to some chat questions not answered during webinar

Click here!

Thank you for your attendance and see you next time!